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Allogeneic hematopoietic cell transplantation (alloHCT) extends the lives of thousands of
patients who would otherwise succumb to hematopoietic malignancies such as leukemias
and lymphomas, aplastic anemia, and disorders of the immune system. In alloHCT, different
immune cell types mediate beneficial graft-versus-tumor (GvT) effects, regulate detrimen-
tal graft-versus-host disease (GvHD), and are required for protection against infections.
Today, the “good” (GvT effector cells and memory cells conferring protection) cannot be
easily separated from the “bad” (GvHD-causing cells), and alloHCT remains a hazardous
medical modality. The transplantation of hematopoietic stem cells into an immunosup-
pressed patient creates a delicate environment for the reconstitution of donor blood and
immune cells in co-existence with host cells. Immunological reconstitution determines
to a large extent the immune status of the allo-transplanted host against infections and
the recurrence of cancer, and is critical for long-term protection and survival after clin-
ical alloHCT. Animal models continue to be extremely valuable experimental tools that
widen our understanding of, for example, the dynamics of post-transplant hematopoiesis
and the complexity of immune reconstitution with multiple ways of interaction between
host and donor cells. In this review, we discuss the rat as an experimental model of HCT
between allogeneic individuals. We summarize our findings on lymphocyte reconstitution
in transplanted rats and illustrate the disease pathology of this particular model. We also
introduce the rat skin explant assay, a feasible alternative to in vivo transplantation studies.
The skin explant assay can be used to elucidate the biology of graft-versus-host reac-
tions, which are known to have a major impact on immune reconstitution, and to perform
genome-wide gene expression studies using controlled combinations of minor and major
histocompatibility between the donor and the recipient.
Keywords: hematopoietic stem cell transplantation, graft-versus-host disease, rodentia, animal models, skin
explant assay
HEMATOPOIETIC CELL TRANSPLANTATION IN HUMANS
AND ANIMALS
At present, approximately 25,000 allogeneic hematopoietic cell
transplantations (alloHCT) are performed each year worldwide,
and the total number of such clinical procedures is predicted to rise
in the future (Savani et al., 2011). AlloHCT can give rise to con-
siderable toxicity and negative side-effects resulting in relatively
high morbidity and mortality with poor quality of life and 5-year
survival rates of 40–60% overall. It is however the only curative
therapy in patients with relatively severe and advanced diseases for
whom other treatment options are limited.
To date, alloHCT is complicated by opportunistic infections,
disease relapse and graft-versus-host disease (GvHD). GvHD is
an immunological condition that is caused by the reactivity of
allogeneic T cells transferred in the stem cell graft from a genet-
ically related or unrelated donor. After activation through recog-
nition of disparate host antigens, alloreactive cells exert patho-
logical damage via cytotoxic mechanisms and cytokine release
on various organs and tissues, primarily the liver, gut, and skin,
of the immunocompromised transplant recipient (Ferrara et al.,
2008). In the clinical setting, relatives are favored over unrelated
volunteer stem cell donors because of genetic similarity with the
patient, reducing the overall risk of transplant failure and adverse
graft-versus-host reactions (GvHR).
Immunity is deficient after alloHCT due to underlying dis-
ease, pre-transplant conditioning, or both, and it takes weeks
to several months or years for the patient’s immune system
to recover (Storek, 2008; Seggewiss and Einsele, 2010; Bosch
et al., 2012). Early after transplantation, the reconstitution of
immune cells in lymphoid organs is inhibited: the primary sites
of white and red blood cell generation, bone marrow and thy-
mus, are damaged by chemotherapy and radiation conditioning,
and they are targeted by GvHD (Krenger and Holländer, 2008;
Shono et al., 2010). Furthermore, immune function is impaired
in elderly patients (Krenger et al., 2011) as both the regenera-
tion of hematopoietic cells in the bone marrow and the thymic
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output of T lymphocytes decrease with age (Dorshkind et al.,
2009).
Deficient and delayed restoration of immunity post-transplant
contributes to the patient’s susceptibility to opportunistic infec-
tions, recurrence of the original disease and occurrence of sec-
ondary malignancies (Toubert et al., 2012). The individual contri-
butions of natural killer (NK) cells, CD8+ cytotoxic T cells, CD4+
helper T cells, B cells, and innate immune cells, and their com-
bined effects on these complications are still not fully understood
(Geddes and Storek, 2007; Bosch et al., 2012).
Moreover, T cell depletion of the graft, when applied to reduce
the risk of GvHD and essential in haploidentical alloHCT between
family members (Kolb, 2008), compromises immune reconsti-
tution, illustrating that grafted “passenger” T cells are needed
for successful engraftment. Depletion of T cells also abrogates
the graft-versus-tumor (GvT) effect, as GvH and GvT effects are
strongly correlated and transplanted donor T cells can either medi-
ate beneficial GvT effects or cause GvHD (Appelbaum, 2001).
The crucial question of how to avoid detrimental GvHR with-
out compromising the curative potential of alloHCT through a
strong GvT effect has yet to be solved by clinical hematologists
and HCT researchers.
THE USEFULNESS OF ANIMAL MODELS IN STUDYING HEMATOPOIETIC
CELL TRANSPLANTATION AND GRAFT-VERSUS-HOST DISEASE
The wish to better understand the dynamic biological processes
between graft and host following transplantation, with the overall
aim to improve the clinical management of alloHCT, has driven
research in the development of adequate laboratory methods and
animal models. The use of such models in transplantation research
has contributed substantially to our current understanding of the
nature of GvHR and its underlying principles in GvHD (Welniak
et al., 2007; Socié and Blazar, 2009). Experimental alloHCT using
mice and dogs have been particularly instrumental for the discov-
ery of a variety of new therapies and for testing their feasibility,
toxicity, and efficacy (Ferrara et al., 2008; Socié and Blazar, 2009).
Inbred rodent strains can be systematically established and
maintained, yielding genetically homogeneous and biologically
well-characterized strains for experimentation. Experiments in
live animals facilitate and accelerate, for example, the study of
genetic effects and mapping of gene associations with observ-
able pathological phenotypes. An array of murine experimental
models that employ donor and host strain combinations designed
for mismatches only in the major histocompatibility complex
(MHC) gene region (H-2 in the mouse), only in minor his-
tocompatibility antigens, or both, are available for the study
of immune reconstitution and GvHD (Schroeder and DiPer-
sio, 2011). Fully incompatible strain combinations, such as the
popular [C57BL/6 (H-2b)→Balb/C (H-2d)] mouse model, are
most often applied. Combinations of mice strains that are MHC
matched but differ in minor histocompatibility antigens, for exam-
ple [B10.D2 (H-2d)→Balb/C (H-2d)], [DBA/2(H-2d)→B10.D2
(H-2d)], or [C3H.SW(H-2b)→C57BL/6 (H-2b)] transplantation
models (Korngold and Sprent, 1987), can mimic fully human
leukocyte antigen (HLA) matched HCT between unrelated indi-
viduals, but not semi-HLA compatible HCT between sibling pairs.
The latter scenario of haploidentical HCT between first-degree
relatives can be modeled by inter-crossing two inbred strains
and using the resulting hybrid progeny of the F1 generation as
recipients of a transfusion of parental leukocytes in so-called
parent-into-F1 models.
The mouse is historically and presently the most widely used
model in biomedical research. However, other animal models
have the potential to complement, validate, and extend the find-
ings from experiments on mice. Studies of alloHCT in dogs
make a case in point as they have added important knowledge
in this field of research (Storb and Thomas, 1985), e.g., the use
of delayed donor lymphocyte infusions to induce a GvT reac-
tion and non-myeloablative (“reduced intensity”) conditioning
regimens to reduce toxicity and morbidity in patients. Murine
models have been employed to test non-myeloablative condition-
ing regimens with reduced irradiation intensity and/or combi-
nation chemotherapy (fludarabine, busulfan, cyclophosphamide,
etc.; Santos and Owens, 1969; Ruggeri et al., 2002; Sadeghi et al.,
2008). Similarly, rat alloHCT models based on chemotherapeutic
conditioning without the need for irradiation have been developed
(Santos and Owens, 1966; Tutschka and Santos, 1975; Okayama
et al., 2004).
Rats offer all the advantages of a rodent experimental model,
such as short generation time and cost effectiveness. Rats are big-
ger than mice (about 10-fold in body weight) and thus yield more
grams of biological material per animal and per cage unit that can
be sampled in the course of experimentation. Their spleens, lymph
nodes, efferent lymph, and peripheral blood contain lymphocytes
that can be readily harvested and serve as organ sources of donor
grafts for transplantation. Hematopoietic stem cells are commonly
obtained from the marrow of large bones (e.g., femurs and tibiae).
Cell grafts enriched in Sca-1+ and CD34+ hematopoietic stem
cells that are being used in patients and experimentally in mice
have not been available for rat models due to the lack of specific
antibody markers for targeted cell purification.
Many genetically defined and well-characterized inbred rat
strains are available for research in transplantation immunology,
and a range of rat alloHCT models have been developed from
these strains during the past decades. Especially the strains Brown-
Norway (BN) and Lewis (LEW) are widely used for fully MHC
mismatched alloHCT (Santos and Owens,1966; Clancy et al., 1976;
Pakkala et al., 2001; Okayama et al., 2004; Zhu et al., 2011; Lin et al.,
2012). Also HCT between haploidentical parental and filial gener-
ations, e.g., transplantation of LEW or BN bone marrow into F1
(BN× LEW) recipients, has been modeled in the rat (Clancy et al.,
1983; Kimura et al., 1995; Ohajekwe et al., 1995; Peszkowski et al.,
1996; Vaidya et al., 1996; Goral et al., 1998; Kobayashi et al., 1998;
Sasatomi et al., 2005; Wolff et al., 2006; Kitazawa et al., 2012). In a
number of these models, engraftment, reconstitution, chimerism,
cell trafficking, and tolerance toward donor cells has been stud-
ied (Clancy et al., 1983; Oaks and Cramer, 1985; Ohajekwe et al.,
1995; Engh et al., 2001; Foster et al., 2001; Okayama et al., 2004;
Itakura et al., 2007; Klimczak et al., 2007; Nestvold et al., 2008;
Zhou et al., 2008; Zhu et al., 2011; Zinöcker et al., 2011a;Lin et al.,
2012). Furthermore, rat models have been employed to test pre-
vention or treatment of GvHD by therapeutic regimens involving
immunomodulatory drugs (Tutschka et al., 1979; Vogelsang et al.,
1986; Vogelsang et al., 1988; Mrowka et al., 1994; Ohajekwe et al.,
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1995; Pakkala et al., 2001; Okayama et al., 2006; Wolff et al., 2006;
Jäger et al., 2007), infusion or induction of various suppressive cell
types (Itakura et al., 2007; Aksu et al., 2008; Nestvold et al., 2008;
Kitazawa et al., 2010; Zinöcker et al., 2011b; Kitazawa et al., 2012;
Zinöcker et al., 2012), UV irradiation (Ohajekwe et al., 1995; Gow-
ing et al., 1998), serum transfusion (Shimizu et al., 1997), surgical
techniques (Kobayashi et al., 1998), and prolonged distribution of
a chemical agent with subcutaneously implanted osmotic pumps
(Fidler et al., 1993).
The MHC is the dominant genomic region that governs mutual
tolerance, rejection, and GvHR between the donor and the host
in alloHCT. The mouse and rat MHC regions are closely related
and share overall similarity with the human MHC (HLA; Kelley
et al., 2005a), however, some important structural differences exist.
In particular, the rat MHC (RT1) differs from the mouse MHC
region in that it encompasses a large number of polymorphic non-
classical MHC class I genes which serve as potential ligands for NK
cell receptors (Vance et al., 1998; Naper et al., 2002; Naper et al.,
2005; Kveberg et al., 2010; Andrews et al., 2012). In addition, the
rat genome encodes a broader spectrum of inhibitory and activat-
ing Ly49 receptors expressed by NK cells compared to the mouse
(Kelley et al., 2005b). Therefore, alloreactive rat NK cells and NK
cell subsets may behave differently than mouse NK cells in the con-
text of transplantation. Transplanted donor-versus-recipient NK
cells mediate both GvT and GvH effects in patients (Ruggeri et al.,
2002). They are thus a key element in the risk of leukemia relapse
after haploidentical alloHCT (Velardi, 2012) and could influence
T cell alloreactivity and the development of GvHR. The consid-
erable differences especially in the NK cell system even between
closely related species like rat and mouse illustrate the importance
of relying on more than one experimental animal model in HCT
research.
The complete genome sequence of Rattus norvegicus has been
resolved in 2004 (Rat Genome Sequencing Project Consortium,
2004). With the advent of commercial cloning technology for rats
(Huang et al., 2011) this species will likely be applied more fre-
quently as a study object in the future. In the following sections, we
will discuss some contributions by which rat models have helped to
advance our understanding of immune reconstitution and GvHR
following alloHCT.
THE RAT AS AN IN VIVO MODEL OF IMMUNE RECONSTITUTION AND
GRAFT-VERSUS-HOST REACTIONS AFTER HEMATOPOIETIC CELL
TRANSPLANTATION
To study the role of GvHR on immune reconstitution in vivo, we
employed experimental transplantation protocols using combina-
tions of rat strains with defined genetic incompatibilities (Engh
et al., 2001; Nestvold et al., 2008; Zinöcker et al., 2012). The
genetic composition regarding the MHC region of relevant rat
strains are listed in Table 1. For experiments on fully incompati-
ble (mismatched at the MHC region as well as non-MHC genes)
alloHCT, we employed a model using Piebald Virol Glaxo (PVG)
rats as the donor strain and BN rats as recipients of transplants.
Conveniently, the genetic make-up of the donor PVG.7B strain
encodes an allele (the RT7.2 allotype) of the CD45 gene (Kampinga
et al., 1990), which facilitates later detection of donor-derived cells
distinguishable from host-derived cells by flow cytometry using
Table 1 | MHC haplotypes of inbred congenic and recombinant rat
strains.
Rat strain MHC subregion
Classical class I Class II Non-classical class I
RT1-A RT1-B/D RT1-CE/N/M
BN n n n
LEW l l l
LEW.1N n n n
PVG c c c
PVG.7B c c c
PVG.1N n n n
PVG.1U u u u
PVG.R23 u a av1
allotype-specific antibody. The genetic background of the PVG.7B
strain is identical with the original PVG strain; both carry the
c haplotype of the rat MHC, i.e., RT1c (Table 1). The recipient
BN strain has a different genetic background and carries the n
haplotype of RT1, RT1n.
The reconstitution of blood and immune cells, especially of
T lymphocytes, has been extensively studied in patients (Holland
et al., 2008; Toubert et al., 2012), however, the mechanisms behind
reconstitution and immunodeficiency and the complex interac-
tions between donor and host cell types in this context remain
incompletely understood. Many useful insights into the under-
lying cellular and molecular processes have been gained from
experiments done mainly in mice. Immune reconstitution and
post-transplant immune responses have been characterized also
in the laboratory rat to some detail, facilitating the design of new
transplantation protocols (Nestvold et al., 2008). The main rat
blood cell types and cell subsets with relevance to HCT and their
standard phenotypic characterization are summarized in Table 2.
One important aim of our studies was to describe in detail
the reconstitution of the lymphocytes that mediate GvT and GvH
effects, i.e., T cells and NK cells, in bone marrow recipients and
in experimental GvHD. The experimental protocol used in these
studies (Zinöcker et al., 2011a; adapted from Nestvold et al., 2008)
is schematically outlined in Figure 1. Recipient rats received a
lethal dose of 900 cGy total body irradiation from a Cesium-137
source emitting β and γ irradiation at an approximate rate of
4 Gy min–1. This conditioning regimen made recipient rats sus-
ceptible to donor engraftment. Donor bone marrow containing
hematopoietic stem cells was obtained from leg bones (femurs
and tibiae). The graft consisted of mononuclear bone marrow
cells that were depleted of T cells by negative selection using mag-
netic beads with anti-αβTCR and anti-CD5 antibodies (cf. Table 2)
prior to transplant (Nestvold et al., 2008). Thus, the primary graft
served to establish stable donor engraftment. In this model, the
transfer of donor-versus-recipient reactive NK cells (Løvik et al.,
1995) contained in the graft should facilitate engraftment and
donor reconstitution. GvT effects can be studied after injecting BN
acute myelocytic leukemia cells, a model of human acute myeloid
leukemia (Martens et al., 1990), into BN recipients (Nestvold
et al., 2008). Transplanted rats were convalescent for 14 days before
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Table 2 | Immunophenotype of rat leukocyte populations.
Cell type Phenotype Antibody Reference
Leukocyte CD45+ OX-1 Sunderland et al. (1979)
MHC-I+ OX-18 Fukumoto et al. (1982)
T lymphocyte CD2+ OX-34 Jefferies et al. (1985)
CD3+ G4.18 Nicolls et al. (1993)
CD5+ OX-19 Dallman et al. (1984)
CD6+ OX-52 Castro et al. (2003)
αβT cell TCRαβ+ R73 Hünig et al. (1989)
CD4 αβT cell CD4+ W3/25 Williams et al. (1977)
OX-38 Jefferies et al. (1985)
CD8 αβT cell CD8α+ OX-8 Brideau et al. (1980)
Naive T cell CD25– OX-39 Paterson et al. (1987)
CD45RChi OX-22 Spickett et al. (1983)
T blast CD25+ OX-39 Paterson et al. (1987)
CD4 T blast CD134+ OX-40 Paterson et al. (1987)
Memory
T cell
CD62L– OX-85 Seddon et al. (1996)
CD45RClo OX-22 Spickett et al. (1983)
Regulatory CD4
T cell
CD45RClo OX-22 Powrie and Mason
(1990)
CD25+ OX-39 Stephens and Mason
(2000)
FoxP3+ FJK-16s Beyersdorf et al. (2005)
Regulatory
CD8 T cell
CD45RClo OX-22 Xystrakis et al. (2004b)
FoxP3+ FJK-16s Han et al. (2007)
γδT cell TCRγδ+ V65 Kühnlein et al. (1994)
B lymphocyte CD45RA+ OX-33 Woollett et al. (1985)
MHC-II+ OX-6 McMaster and Williams
(1979)
Activated B cell CD80+ 3H5 Maeda et al. (1997)
CD86+ 24F Maeda et al. (1997)
NK lymphocyte CD3– G4.18 Nicolls et al. (1993)
CD161a+ 3.2.3 Na et al. (1992)
(NKR-P1A) 10/78 Chambers et al. (1992)
NKT lymphocyte CD3+ G4.18 Nicolls et al. (1993)
CD161a+ 3.2.3 Na et al. (1992)
(NKR-P1A) 10/78 Chambers et al. (1992)
Macrophage MHC-II+ OX-6 McMaster and Williams
(1979)
CD172a+ (SIRPα) OX-41 Robinson et al. (1986)
CD11c+ OX-42 Robinson et al. (1986)
CD68+ ED1 Dijkstra et al. (1985)
ED2a Dijkstra et al. (1985)
Dendritic cell MHC-II+ OX-6 McMaster and Williams
(1979)
CD172a+ (SIRPα) OX-41 Robinson et al. (1986)
CD11c+ OX-42 Robinson et al. (1986)
αE2 integrin OX-62 Brenan and Puklavec
(1992)
Phenotypic markers of rat leukocyte populations and subpopulations are summa-
rized together with available antibodies commonly used for their flow cytometric
detection. Comprehensive lists of rat antigens and specific antibodies have been
published by Puklavec and Barclay (2001) and van den Berg et al. (2001). A
list of OX antibodies can be found online at http://users.path.ox.ac.uk/∼ciu/mrc-
mabs.html
aNo CD designation is assigned for the cognate antigen.
FIGURE 1 | Schematic outline of the transplantation protocol applied
in the MHC mismatched rat model. (A) BN rats served as recipients and
PVG.7B rats as bone marrow and lymph node donors for bone marrow
transplantation (BMT) and donor lymphocyte infusion (DLI), respectively, in
fully MHC-incompatible alloHCT performed as shown in (B). Recipient rats
were lethally irradiated (900 cGy), rescued by an intravenous injection of
donor bone marrow cells and 14 days later received a graded dose of donor
lymph node cells to invoke fatal GvHD. Controls received sham treatment
(injection without cells) instead of DLI. Blood samples were collected in
weekly intervals from the day of DLI for subsequent analysis of
reconstitution and chimerism.
GvHD was induced in a cell-dose dependent manner by a single
infusion of donor lymphocytes (DLI; cf. Figure 1) from lymph
nodes. Alternatively,GvHD can be invoked by transfusion of donor
cells derived from the spleen or peripheral blood, and the latter
source is highly relevant with regard to clinical GvHD, which is
commonly caused by the transfer of T cells contained in a donor
blood graft or donor lymphocyte transfusion.
T cells, NK cells, and NKT cells
With respect to lymphocyte reconstitution in recipients of clin-
ical HCT, NK cells recover relatively swiftly (weeks) and T cell
reconstitution happens more slowly (months to years; Storek
et al., 2008). In our hands, both NKT and NK cells (as defined
by CD3 and NKR-P1 surface expression; cf. Table 2) of donor
origin were rapidly generated in animals transplanted with T
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cell-depleted bone marrow. NKT and NK cells of host origin
were not detected in the circulation 2 weeks after HCT (Zinöcker
et al., 2011a). Donor T cells showed a significantly slower pace of
reconstitution in these animals, and reached approximately 90%
donor chimerism in the blood only several months after transplant
(Zinöcker et al., 2011a). Thus, the overall patterns of NK, NKT,
and T lymphocyte reconstitution were similar to those observed
in patients, albeit with accelerated kinetics as might be expected
from a relatively short-lived rodent species.
Donor CD4+ T cells showed a tendency to reconstitute slightly
more slowly than did donor CD8+ T cells (Zinöcker et al., 2011a),
which is also comparable with known clinical data (Seggewiss and
Einsele, 2010). Rats that received an infusion of donor lymph
node cells and subsequently developed GvHD displayed full donor
chimerism of CD4+ and CD8+ T cells shortly after DLI, coin-
ciding with the onset of disease symptoms. This increase very
likely reflected the activation by allo-antigens and rapid expan-
sion of donor CD4+ and CD8+ T cell clones in the host. Any
remaining host T cells were probably cleared by alloreactive
donor cells.
Memory T cells
We also noted that donor-derived CD62L-expressing naive T cells
were less frequent in the peripheral blood of rats that developed
GvHD compared with healthy bone marrow-transplanted con-
trols (Zinöcker et al., 2011a). This finding may likely be due to the
loss of CD62L surface expression in the course of T cell activation
as measured by the concomitant increase of CD25 and CD134
activation markers on CD4+ and CD8+ T cell populations (cf.
Table 2). Although we did not specifically investigate a memory
T cell phenotype in our study, we speculate that donor mem-
ory T cells may expand in the presence of host allo-antigens and
allo-activation as CD62L− T cells were more frequent in the cir-
culation in rats with GvHD. CD44+ CD62L− memory T cells that
are generated in response to pathogens during infection as well as
other antigens have been reported not to cause GvHD (Anderson
et al., 2003; Chen et al., 2004). In line with these studies, Xystrakis
et al. (2004a) have employed a parent-into-F1 HCT model and
showed that CD4+ CD45RClo T cells containing mainly memory
T cells, in contrast to CD4+ CD45RChi T cells containing mainly
naive T cells, failed to induce acute or chronic GvHD in recipi-
ent rats. Conversely, transplanted memory T cells not specifically
primed to allo-antigens can have a considerable potency to induce
GvHD (Zheng et al., 2009). Therefore, the capacity of differenti-
ated memory T cells to elicit a GvHR may depend on the nature
of their primary antigen encounter.
Regulatory T cells
Furthermore, we found that host-derived FoxP3-expressing CD4+
CD25+ T cells, comprising a regulatory T cell subtype (Beyers-
dorf et al., 2005), reconstituted relatively quickly and were present
at normal levels in peripheral blood at 4 weeks post-transplant
(Zinöcker et al., 2011a). It has been shown previously in mice that
recipient CD4+ CD25+ T cells can resist irradiation and regu-
late chronic GvHD (Anderson et al., 2004). Donor-type FoxP3+
regulatory T cells, on the other hand, did not amount to sig-
nificant numbers in the blood of transplanted rats at any time
point post-transplant. Strikingly, and in contrast to transplanted
controls which did not receive DLI, rats that suffered from GvHD
failed to reconstitute FoxP3+ regulatory T cells completely. We
speculate that the absence of regulatory T cells is a major contribut-
ing factor in the lack of ability of these animals to avert alloreactiv-
ity as they uniformly developed lethal GvHD. Another regulatory
T cell subtype that was defined as CD8+ CD45RClo FoxP3+ in the
rat (cf. Table 2) suppressed alloreactive donor CD4+ T cells in vitro
and prevented experimental GvHD in vivo (Xystrakis et al., 2004b).
Decreased FoxP3 expression (Miura et al., 2004) and frequency of
regulatory T cells (Zorn et al., 2005; Rieger et al., 2006; Magenau
et al., 2010) has been associated with the incidence of GvHD in
patients. Furthermore, CD4+ CD25+ regulatory T cells have been
shown to suppress host-reactive T cells and reduce acute GvHD
in murine models (Cohen et al., 2002; Hoffmann et al., 2002; Tay-
lor et al., 2002; Edinger et al., 2003). Alleviation of GvHD after
infusion of donor-derived CD4+ CD25+ regulatory T cells has
recently been reported in some patients (Brunstein et al., 2011; Di
Ianni et al., 2011), although these phase I clinical trials were not
powered to assess the efficacy of this treatment modality and did
not include control subjects. The therapeutic potential of regula-
tory T cell induction or adoptive transfer in GvHD prevention is
currently under clinical exploration (Leventhal et al., 2012).
B cells and antibodies
In transplanted rats, B cells recover gradually in host lymphoid
organs and peripheral blood with kinetics similar to that of T
cells (Renkonen, 1986). This is consistent with what is known of
B cell reconstitution in patients who receive an allogeneic donor
transplant (Bosch et al., 2012), as is the finding that B cell recon-
stitution is delayed during acute GvHD (Renkonen, 1986; Bosch
et al., 2012). B cells did not recover in the skin, lungs, or the
gut of host rats that developed acute GvHD, but accumulation
of immunoglobulin-producing cells was observed in the inflamed
liver (Renkonen et al., 1986). B cells are thought to participate in
the pathogenesis of GvHD (Shimabukuro-Vornhagen et al., 2009),
possibly by presenting allo-antigens and by secreting auto- and
alloreactive antibodies.
Disparate MHC molecules and minor histocompatibility (non-
MHC) antigens of both donor and host type co-exist in radiation
chimeras, by which B cells can be activated to produce allo-
antibodies either against donor antigens (on hematopoietic cells)
or against host antigens (mainly non-hematopoietic tissue). Puta-
tive donor-derived allo-antibodies will therefore bind mainly to
tissue components of the host and may be difficult to detect in the
serum unless circulating donor cells are screened for B cell recep-
tor specificities. We know that the transfusion of PVG T cells into
semi-allogeneic F1 (PVG×DA) hybrid recipients induces auto-
antibodies against basal membranes of the skin (Rolstad, 1985).
Increased serum levels of antibodies against heat-shock proteins
are associated with acute and chronic GvHD (Goral et al., 1995,
2002).
B cells play an important role in the etiology of chronic GvHD
as increased auto-antibody titers and other autoimmune-typical
symptoms are hallmarks of this disease (Ferrara et al., 2008).
Laboratory rodents have been used to model chronic GvHD exper-
imentally (Vogelsang et al., 1988; Schroeder and DiPersio, 2011).
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Spleen cell transfer without bone marrow transplantation from
either BN or LEW donor strains induced autoreactive antibodies
that are typical of an autoimmune-like chronic GvHR in F1
(LEW×BN) hybrid rats (Tournade et al., 1990; Xystrakis et al.,
2004a). Interestingly, transfusions of LEW splenocytes resulted
in acute GvHD and death of F1 recipients, while transfusions of
BN splenocytes caused no disease (Tournade et al., 1990; Xys-
trakis et al., 2004a). This may be due to different genetic factors
in the respective donor strains and T cell responses that differ
in the pattern of cytokine release upon allostimulation (Bernard
et al., 2010). Studies done in our labs support the hypothesis that
the quality of the allogeneic T cell response is important and
depended on the tissue source: peripheral T cells typically induced
acute GvHD (Nestvold et al., 2008) while bone marrow-derived
T cells induced a more chronic form of the disease (Naper et al.,
2010).
ALLO-TRANSPLANTATION IN A SEMI-COMPATIBLE RAT MODEL
Hematopoietic cell transplantations using fully MHC mismatched
donors are not performed in the clinic because of the excessively
high risk of GvHD. Previous efforts in our lab to generate a semi-
compatible (haploidentical) HCT model by cross-breeding inbred
PVG and BN rats failed because of what appeared to be a significant
heterosis effect that rendered the F1 (PVG×BN) offspring highly
aggressive and impossible to handle. In another effort to design a
model that reflects the clinical reality better than the completely
mismatched [PVG.7B→BN] transplantation model, we selected
rat strains that were partly matched at the MHC region. The PVG-
RT1r23 strain (PVG.R23) and the PVG-RT1ustrain (PVG.1U) are
partially compatible: PVG.1U rats express the u-u-u haplotype of
RT1 and PVG.R23 rats the intra-MHC recombinant u-a-av1 hap-
lotype, i.e., they are matched in the classical class I (RT1-A), but
not the class II (RT1-B/D) and non-classical class I (RT1-CE/N/M )
MHC regions (cf. Table 1). The strains are matched for minor his-
tocompatibility antigens as both express the same class III MHC
genes on the PVG genetic background. Disparity for either the
class II locus RT1-B/D or non-MHC genes elicits fatal GvHD in
the rat, while the class I loci RT1-A and RT1-CE/N/M, respectively,
have little or no effect (Oaks and Cramer, 1985). Therefore, in the
[PVG.1U→PVG.R23] combination, GvHD is primarily due to
the mismatch of class II genes. Dahlke and coworkers (Jäger et al.,
2007) have made use of a similar semi-allogeneic transplantation
model, where a mismatch only in MHC class II genes induced
lethal GvHD in [LEW.AR1→ LEW.AR2] transplanted rats. We
used PVG.R23 as HCT recipients and PVG.1U rats as marrow
donors, respectively, in our experiments (Zinöcker et al., 2012).
This model was designed to better mimic a clinical setting where
some degree of mismatch of the donor MHC is permissible to
perform a HCT procedure on patients in need of a transplant
(Petersdorf, 2007). It should not be inferred from this model,
however, that it can replicate the setting of haploidentical HCT
in humans, where siblings, who share half of their MHC genes
and a range of minor histocompatibility antigens with the recipi-
ent, serve as stem cell donors. Rather, the semi-compatible rat HCT
model reflects a transplantation scenario in which polymorphisms
of both MHC and non-MHC genes contribute to the induction of
acute GvHD.
The HCT protocols described above (cf. Figure 1) resulted in
the onset of a rapid wasting disease with severe loss of weight that
was typical of acute GvHD and was fatal in 90–100% of recipients
(Zinöcker et al., 2011a,b, 2012). The kinetics of disease progression
were similar in both the MHC mismatched [PVG.7B→BN] and
the partially matched [PVG.1U→PVG.R23] model (Zinöcker
et al., 2012). The titrated DLI dose required to reproducibly invoke
lethal acute GvHD in the latter model (9× 106 T cells from lymph
nodes) was higher compared to the former (5× 106 T cells from
lymph nodes; Zinöcker et al., 2012). Recipients were monitored
closely over time for GvHD-typical symptoms which were quan-
tified using a scoring table (Zinöcker et al., 2011a) adapted from
Cooke et al. (1996).
Acute GvHD primarily affects the liver, the intestine and the
skin (Ferrara et al., 2008). In our models, severe GvHD symp-
toms were observed (Zinöcker et al., 2011a). The skin was tar-
geted by GvHR; poor grooming, ruffling, fur loss, skin flaking,
and occasionally, skin lesions were manifest. These observations
were confirmed histologically, with GvHD symptoms present in
the skin (Figure 2) and secondary lymphoid organs, spleen and
lymph nodes (Zinöcker et al., 2011a). Histological evaluation of
the liver and gastrointestinal tract revealed no significant patholog-
ical changes of these organs. Therefore, results from these models
pertain primarily to cutaneous GvHD. The absence of observable
pathology of the liver and the gut could simply depend on the rapid
onset and progression of GvHD in host rats, marked by dehydra-
tion and severe weight loss, before histopathology of other organs
became manifest. On the other hand, they may reflect significant
differences in the underlying mechanisms of disease development
affecting distinct target sites in these models.
Despite the considerable genetic barriers in the fully and par-
tially mismatched alloHCT settings, we reproducibly established
stable allogeneic rat chimeras by transplanting large numbers of
bone marrow cells that were extensively depleted of T cells. These
protocols demonstrate the central importance of T cells in GvHD
as is the case in humans (Ferrara et al., 2008), and, as defined
numbers of donor T cells were sufficient to subsequently induce
severe acute GvHD, these models may serve to investigate the con-
tributions of T cells and other cell types to GvHR in vivo and to
manipulate such alloimmune responses with drugs or different
modes of cellular therapy.
One important advantage of using the rat model, which we
discuss further in the following section, is the availability of corre-
sponding in vitro models of GvHR, especially the rat skin explant
assay. This model resembles key features of clinical GvHR in a
simple experimental setting that can be highly standardized and
easily manipulated.
THE RAT SKIN EXPLANT ASSAY
Robust risk estimates of GvHD incidence and severity would
allow clinicians to intervene at the stage of donor selection,
pre-transplant conditioning, and choice of immunosuppressive
treatment in the course of transplantation. It is well established
that disparities in minor and major human leukocyte antigens
between patients and donors can cause GvHD. A number of
human biomarkers of acute and chronic GvHD for prediction
of treatment outcome and mortality have been identified recently
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FIGURE 2 | Histopathology of GvHD in rats transplanted with
allogeneic, fully MHC mismatched bone marrow. Grade II (A) and
III–IV (B) pathology is manifest in the skin of BN rats that suffered from
acute GvHD after bone marrow transplantation and donor lymphocyte
infusion from PVG donors. Pathological grading was performed based
on the GvHD classification originally described by Lerner et al. (1974)
for human skin GvHD. Skin was removed from the paws at autopsy and
tissue sections were stained with hematoxylin and eosin. These
photographs are reprinted from Novota et al. (2008) with permission
from the publisher.
(Paczesny et al., 2009; Levine et al., 2012b) and their reliability was
prospectively evaluated in patients (Levine et al., 2012a).
The skin explant assay is an in vitro model which can pre-
dict GvHD in patients with high sensitivity and specificity. It was
prospectively tested as a method to predict GvHD incidence and
severity in a donor/patient cohort by Vogelsang et al. (1985). Sev-
eral studies used the skin explant assay to predict the likelihood of
acquiring GvHD and reported correlation rates of 80–90% with
clinical outcome, which proved the skin explant assay superior to
other in vitro models that had been designed for this purpose (Svi-
land and Dickinson, 1999; Dickinson et al., 2001; Hromadnikova
et al., 2001; Sviland et al., 2001; Wang et al., 2006). The accuracy of
the prediction by skin explant, however, was dependent on the type
of GvHD prophylaxis and conditioning regimens used. Matched
unrelated donor transplants, including T cell depletion protocols,
gave understandably low prediction rates (Wang et al., 2006).
The skin explant closely resembles the histopathology of cuta-
neous GvHD and allows the study of pathophysiological processes
related to GvHR (Sviland and Dickinson, 1999; Dickinson et al.,
2001; Dickinson et al., 2002). Histological grading of the skin
explant, from grade I to grade IV with increasing severity (Lerner
et al., 1974), represents a standardized method to evaluate the risk
for selected donor/recipient combinations before transplantation.
One problem for a broad application of the assay in experimental
studies is the shortage and genetic heterogeneity of skin biopsies
from healthy donors. To overcome this problem and to reduce the
need for animal experimentation, we developed a rat skin explant
assay that can complement and in part replace transplantations in
rodents. This assay can be highly standardized and results are not
hampered by undefined genetic differences between tissue sam-
ples which cannot be avoided in human studies. The experimental
procedure is described in detail elsewhere (Novota et al., 2008).
Briefly, lymphocytes from the spleens of donors are stimulated
with irradiated lymphocytes from the spleens of recipients in a
mixed lymphocyte reaction for 7 days, then transferred to a cul-
tured skin biopsy of the recipient and co-incubated for three more
days. The GvHR is then evaluated and scored by histology using
the same criteria as for grading GvHR in human skin explants
(Sviland and Dickinson, 1999). Using genetically well-defined
inbred strains, we showed that combinations with differences in
major histocompatibility antigens usually led to grade III or IV
GvHR (Novota et al., 2008). GvHR was on average less severe
(grade II) in MHC congenic strain combinations which are only
mismatched in minor histocompatibility antigens than in com-
binations with major or minor plus major histoincompatibility
(Novota et al., 2008). The histopathology of cutaneous GvHR in
these skin explants closely resembled the histopathology of GvHR
in human skin explants (Figure 3). We were also interested to
determine whether the rat skin explant assay could resemble, in
addition to histological features of GvHD, the molecular profile of
GvHD in the patient. In our initial study (Novota et al., 2008),
we focused on MHC-linked Hsp70 genes because the expres-
sion of stress-inducible heat shock protein 70 has been correlated
with the GvHR grading in human skin explants (Jarvis et al.,
2003). Indeed, the relative expression of the Hsp70-1 (Hspa1b)
and Hsp70-2 (Hspa1a) genes correlated with the grade of GvHR
in rat skin explants (Novota et al., 2008), indicating that certain
molecular patterns of GvHR are conserved between human and
rat skin explants.
This result encouraged us to use the rat skin explant assay for
searching new genetic biomarkers of GvHR. In an expression pro-
filing study with special emphasis on MHC and NK gene complex
(NKC) genes, 11 MHC, 6 NKC, and 168 genes in other genomic
regions were identified to be regulated during GvHR in rat skin
explants (Novota et al., 2011). For MHC and NKC genes, the
results were verified by real time PCR experiments on samples
from other skin explant assays using different strain combina-
tions, on skin with cutaneous GvHD from transplanted rats, and
on samples from human skin explant assays. The genes that were
confirmed to be regulated also in human skin explant samples with
GvHR included TAP1, PSMB8, C2, UBD, and OLR1 (Novota et al.,
2011). These genes have known polymorphisms in humans and
are therefore potential candidates for diagnostic biomarkers in the
clinic.
The rat skin explant assay is a promising tool not only for the
identification of candidate genes regulated in GvHR but also for
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FIGURE 3 | Comparison of the histopathology of GvHR in human
skin explants and rat skin explants. GvHR of increasing severity
occur during co-incubation of pre-stimulated, allogeneic lymphocytes
with explants of rat skin (A–D) or human skin biopsies (E–H). Grade I
[mild vacuolization of epidermal cells with occasional dyskeratotic
bodies; (A,E)], grade II [diffuse vacuolization of basal cells with
scattered dyskeratotic bodies; (B,F)], grade III [formation of
subepidermal clefts; (C,G)], and grade IV [complete separation of the
epidermis from the dermis; (D,H)] pathological changes are similar in
human and rat skin explants. The photographs of the rat skin explants
depicted in (A–D) were reprinted from Novota et al. (2008) with
permission from the publisher.
the functional evaluation of GvHR in an experimental system. As
with the human skin explant assay, it can be used to investigate the
role of cytokines (Dickinson et al., 1991; Dickinson et al., 2002;
Wang et al., 2002) and innate immunity in GvHR, e.g., heat-shock
protein 70 (Jarvis et al., 2002, 2003), the roles of NK cells, den-
dritic cells (Wilson et al., 2009), regulatory T cells (Wang et al.,
2009; Mavin et al., 2012), and subsets of T cells (Dickinson et al.,
2002) as well as Fas expression (Ruffin et al., 2011).
CONCLUSION
The laboratory rat is a useful biological model organism for the
study of alloHCT, immune reconstitution, and transplant-related
complications. While the mouse has found its place in the lime-
light of comparative and translational immunology, a steadily
increasing number of insightful investigations in the rat have been
undertaken. When compared to mice and other animal models,
experiments in rats can add instrumental insights into the con-
sistency or divergence of findings made in related mammalian
species. We found that after transplantation, host rats reconsti-
tuted peripheral regulatory T cells of host but not donor origin,
and were deficient of any such cells when suffering from severe
acute GvHD.
Important aspects of alloHCT, such as GvHR and tolerance
mechanisms that are highly relevant for immune reconstitution
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can now be addressed ex vivo in the rat skin explant model.
Therefore, this assay represents a valuable and accessible research
tool that complements the in vivo model. These research tools cur-
rently available in the rat model might also prove to be important
for other areas of research.
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